A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-3383 in Healthy Volunteers
Latest Information Update: 10 Jun 2025
At a glance
- Drugs SGB 3383 (Primary)
- Indications Haemolytic uraemic syndrome; IgA nephropathy; Membranoproliferative glomerulonephritis
- Focus Adverse reactions
- Sponsors SanegeneBio
Most Recent Events
- 05 Jun 2025 New trial record
- 20 May 2025 According to a SanegeneBio media release, the company has received clinical trial approval from the Center for Drug Evaluation (CDE) under China's National Medical Products Administration (NMPA), for the treatment of complement-mediated kidney diseases, including IgA nephropathy (IgAN), C3 glomerulopathy (C3G), Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN), atypical Haemolytic Uraemic Syndrome (aHUS), etc.